AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Clinical trial NCT00146913 · UNKNOWN
Trial details
- NCT number
- NCT00146913
- Sponsor
- Hospices Civils de Lyon
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2004-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.